
    
      The primary aim of this study is to investigate the clinical efficacy of eszopiclone for the
      treatment of schizophrenia-related insomnia over 8 weeks. A two-week, single-blind placebo
      phase followed the double-blind phase to evaluate rebound and withdrawal effects after abrupt
      discontinuation.
    
  